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Background: It is currently unclear whether a correlation exists between N-myc downstream-regulated gene 2
(NDRG2) expression and oesophageal squamous cell carcinoma (ESCC). The aim of this study was to examine the
underlying clinical significance of NDRG2 expression in ESCC patients and to investigate the effects of NDRG2
up-regulation on ESCC cell growth in vitro and in vivo.
Methods: Immunohistochemistry was used to determine the level of NDRG2 expressions in ESCC tissue, which was
then compared to specific clinicopathological features in the patient and tissue specimens. Factors associated with
patient survival were analysed. Moreover, the effects of up-regulating NDRG2 expression on the growth of an ESCC
cell line were examined by MTT, colony formation, DNA replication activity and nude mouse model assays.
Results: Notably low expression of NDRG2 in ESCC patients was inversely associated with clinical stage, NM
classification, histological differentiation and patients’ vital status (all P < 0.05). ESCC patients expressing high levels
of NDRG2 exhibited a substantially higher 5-year overall survival rate than NDRG2-negative patients. Furthermore,
NDRG2 over-expression reduced the proliferation, colony formation and DNA replication activity in ESCC cells, as
well as inhibiting the growth of ESCC cells in vivo.
Conclusion: The present experiments demonstrated that NDRG2 may be a diagnostic and prognostic marker in
patients with ESCC, and up-regulation of NDRG2 might act as a promising therapeutic strategy for aggressive ESCC.
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Oesophageal carcinoma is regarded as the eighth most
common malignant cancer and sixth most frequent
cause of cancer death worldwide [1]. Oesophageal squa-
mous cell carcinoma (ESCC) is the most common
pathological type in developing nations, particularly in
China [2-4]. It has been reported that there are 167,200
cases of oesophageal cancer in China each year, out of a
global total of approximately 310,400 cases [5]. Despite
improvements in its detection, surgical resection, and
adjuvant therapy, the 5-year overall survival rate for
oesophageal cancer is approximately 15-24% [6]. Current
chemo/radiotherapy conditions act sub-lethally, but they* Correspondence: zhangjuliang75@gmail.com
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reproduction in any medium, provided the orcannot effectively suppress the proliferation of ESCC
cells. Thus, a deeper understanding of the molecular
mechanisms involved in the high rate of proliferation
and significant invasion of ESCC cells will allow for the
development of an adjuvant therapy to improve current
treatment options.
NDRG2, a member of the N-myc downstream-regulated
gene family, belongs to the alpha/beta hydrolase super-
family. It was first cloned at our university from a normal
human brain cDNA library by subtractive hybridization
(GenBank accession no. AF159092) and is regarded as a
tumor suppressor gene that is transcriptionally repressed
by c-Myc [7-9]. Accumulated evidence indicates that
NDRG2 is down-regulated or undetectable in many hu-
man cancers [10,11]. Recently, it has been shown that
breast cancer cells have low or undetectable NDRG2 ex-
pression, compared with high levels in normal tissues [11].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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proliferation and enhance apoptosis in many malignant
tumors [12]. In addition, NDRG2 could inhibit breast
cancer angiogenesis by up-regulating p53 and down-
regulating of VEGF [13]. These findings suggest that the
expression of NDRG2 is inversely related to cell prolifera-
tion, especially in terms of cancer cell proliferation. How-
ever, the effects of NDRG2 expression in ESCC remain
unclear.
The objective of this study was to investigate NDRG2
expression and its clinical significance in ESCC and to
further explore the effects of NDRG2 up-regulation on
ESCC cell growth. In this study, western blot analysis
and immunohistochemistry methods were used to exam-
ine NDRG2 expression. The correlation of NDRG2 ex-
pression with clinicopathological features specific to
ESCCs was also assessed. Furthermore, using an adeno-
virus NDRG2 expression system, we verified the effects
of Ad-NDRG2 on proliferation, clone formation number,
DNA replication activity of Eca-109 cells, and the
growth of tumors in a nude mouse model.
Methods
Patient information and tissue specimens
This study was approved by the Ethics Committee of the
Fourth Military Medical University, and all patients
agreed to participate in this study. Fresh oesophageal
squamous cell carcinoma specimens were collected from
143 patients at the Xijing Hospital and Tangdu Hospital
of the Fourth Military Medical University (Xi’an, China)
from 2003 to 2005. ESCC tissues were obtained from
resected tumors and confirmed by pathological review.
ESCC specimens were staged in accordance with the
American Joint Cancer Committee/Union for Inter-
national Cancer Control (AJCC/UICC) classification
guidelines. The grading and histopathology subtyping of
ESCC specimens were based on WHO criteria.
Immunohistochemistry
Immunohistochemical staining was performed to assess
NDRG2, cyclinD1 and Ki67 protein expression, as
described previously [14]. For immunohistochemistry,
formalin-fixed tumor tissues were embedded in paraffin,
and serial 4 μm sections were obtained using a Leica
microtome. For staining, tumor sections were depara-
ffinised in toluene, rehydrated in an alcohol gradient,
and permeabilised in citrate buffer (pH 6.0). Sections
were then quenched with 3% H2O2 for 5 min to elimin-
ate endogenous peroxidase activity and washed in PBS.
Sections were incubated overnight with different anti-
bodies, followed by NDRG2, cyclinD1 or Ki67 antibodies
incubation with a biotinylated goat anti-rat or anti-
rabbit IgG antibody for 15 min. After washing, sections
were incubated with streptavidin peroxidase, lightlycounterstained with hematoxylin, and observed under a
photomicroscope.
Staining evaluation
Fresh oesophageal squamous cell carcinoma specimens
were collected from 143 patients at the Xijing Hospital
and Tangdu Hospital of the Fourth Military Medical
University (Xi’an, China) from 2003 to 2005. NDRG2 ex-
pression was detected in all specimens. Tissue speci-
mens were examined separately by 2 pathologists under
double-blinded conditions. The molecular expression
was scored as positive if >10% of cells had moderate-to-
strong staining. Expression was scored as negative if ei-
ther cytoplasmic or membranous staining were noted in
< 10% of cells or if neither cytoplasmic nor membranous
staining were observed [15].
Cell lines and reagents
Normal human oesophageal epithelial cell line HEEC
and five ESCC cell lines (EC8712, KYSE30, Eca-109,
KYSE70 and KYSE150) were obtained from American
Type Culture Collection(ATCC, USA) and maintained in
RPMI 1640 medium (Invitrogen, USA) supplemented
with 10% foetal bovine serum (FBS, Life Technologies,
USA), 100 units/ml penicillin G sodium (Sigma, USA),
and 100 μg/ml streptomycin sulphate (Sigma, USA).
Cells were grown at 37°C in a humidified atmosphere
containing 5% CO2. A mouse anti-human NDRG2 mon-
oclonal antibody (1:1000 dilution) was purchased from
Abcam (UK). A rabbit anti-human β-actin monoclonal
antibody (1:3000 dilution) was purchased from Biomics
Corporation (China). MTT and western blot kits were
from Sigma.
Immunofluorescence assay
Cells were fixed in 4% paraformaldehyde for 30 min at
room temperature and permeabilised with PBS con-
taining 0.1% Triton X-100 for 10 min. After washing 3
times with PBS, cells were incubated with 50 μl of
NDRG2 primary antibody (1:200) at 4°C overnight.
Then, the cells were incubated with CY3 (1:400) at room
temperature for 2 h before applying the mounting
medium (containing DAPI (Sigma; 1:100) for nuclear
counterstaining). Cells were washed three times with
PBS before observation. The results were analysed using
a fluorescence microscope (Olympus).
Gene infection
A multiplicity of infection (MOI) of 40 was determined
experimentally for Eca-109 cells. Cells were seeded in 6-
well plates at a density of 5 × 105 cells/well and grown to
approximately 80% confluence. After removing the
medium, adenovirus-expressing NDRG2 (Ad-NDRG2)
or the negative control gene LacZ (Ad-LacZ) was added
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with fresh 1640 supplemented with 10% FBS and incu-
bated for 48 h.
Western blot
For whole-cell extracts, cells were washed with ice-cold
PBS and collected by scraping. Cell pellets were homo-
genised in extraction buffer (50 mM Tris–HCl, 0.1% SDS,
150 mM NaCl, 100 mg/ml phenylmethylsulfonyl fluoride,
1 mg/ml aprotinin, 1% NP-40, and 0.5% sodium or-
thovanadate), incubated at 4°C for 20 min and then
centrifuged for 20 min at 12,000 rpm. Protein levels in the
extracts were quantified using the Bio-Rad DC protein
assay. For western blots, 80 μg of whole-cell extract was
resolved on 12% SDS-polyacrylamide gels, then trans-
ferred onto nitrocellulose membranes (0.45 μm, Millipore,
USA) in 25 mM Tris-base, 190 mM glycine, and 20%
methanol using a semi-dry blotter. Membranes were
blocked with 5% fat-free milk and 0.1% Tween-20 in Tris-
buffered saline (TBS). Primary antibodies were used at the
concentration recommended by the suppliers. Detection
of monoclonal and polyclonal antibodies was performed
using horseradish peroxidase-conjugated goat anti-mouse
/anti-rabbit immunoglobulins, respectively, and an en-
hanced chemiluminescence (ECL) substrate.
Cell proliferation assay
Cell growth following infection was evaluated by an
MTT assay. Cells were seeded in a 96-well plate (1 × 103
cells/well) and incubated for different time periods. At
different time points post-infection, the cells were incu-
bated with 0.5 mg/ml MTT (Sigma). Four hours post-
infection, the medium was replaced with 150 μl dimethyl
sulfoxide (DMSO) (Sigma) and vortexed for 10 min.
Absorbance (A) was then recorded at 570 nm using an
Easy Reader 340 AT plate reader (SLT-Labinstruments,
Salzburg, Austria). Relative optical density (OD) values
were calculated as percentages of the control. All experi-
ments were performed three times independently.
Plate colony formation assay
For colony formation assays, 1 × 103 cells infected with
different adenovirus constructs were seeded into 60 mm
dishes with 5 ml of 1640 medium supplemented with
10% FBS. After 10 days, the resulting colonies were
rinsed with PBS, fixed with methanol at -4°C for 5 min,
and stained with Giemsa (Sigma) for 20 minutes.
Counting was performed only on clearly visible colonies
(diameter > 50 μm).
DNA replication activity assay
DNA replication activity was examined using BrdU
(5-Bromo-2-deoxyUridine). Cells grown on coverslips
(Fisher) were infected with Ad-LacZ and Ad-NDRG2.Two days after infection, the cells were incubated with
BrdU for 1 h and stained with an anti-BrdU antibody
(Roche) according to the manufacturer’s instructions. The
cells were then cultured in the mounting medium
(containing DAPI (Sigma, 1:100) for nuclear counter-
staining). Cells were washed three times with PBS before
observation. The results were analysed using a fluores-
cence microscope (Olympus).
Xenograft study in nude mice
For inoculation into nude mice, Eca-109 cells were
washed with PBS, digested with trypsin, and res-
uszpended in serum-free 1640 medium. After centrifuga-
tion (800 rpm), cell pellets were suspended in 1640
medium. The cell suspension (5 × 106 cells in a volume
of 100 μl PBS) was injected subcutaneously into the hind
legs of 4-week-old female BALB/C athymic (nu/nu) mice
(SLAC Laboratory Animal Company, Shanghai, China)
[16]. When tumors reached a volume of 200 mm3, the
mice were arbitrarily assigned to different groups (n = 6
each) to receive intratumoural injections of 109 PFU Ad-
NDRG2, Ad-LacZ, or PBS. Intratumoural injections
were repeated every 3 days for a total of 24 days. Tu-
mors were measured (perpendicular diameters) every
day and their volumes calculated. On day 24, the mice
were sacrificed, and their tumors removed for analysis.
Tumor volumes were calculated based on calliper mea-
surements of the length and width of the lesions using
the following formula: 0.5 × length × width2. The growth
curve was then derived from these data.
All experimental procedures were conducted in accord-
ance with the Detailed Rules for the Administration of
Animal Experiments for Medical Research Purposes is-
sued by the Ministry of Health of China and received eth-
ical approval by the Animal Experiment Administration
Committee of the Fourth Military Medical University
(Xi’an, P. R. China). All efforts were made to minimise the
animals’ suffering and to reduce the number of animals
used.
Statistical analysis
Experiments in vitro were performed 3 times, and each
experiment was performed in triplicate. Data from all
quantitative assays are expressed as the mean ± standard
deviation (SD) and were analysed statistically using a
one-way ANOVA and the independent-samples t-test. In
the in vivo study, associations between NDRG2 expres-
sion and categorical variables were analysed by using the
chi-square test or the Fisher exact test, as appropriate.
Correlations between NDRG2 expression and categorical
variables were analysed by using the Spearman correl-
ation test. Survival curves for both NDRG2-high and
NDRG2-low expression patients were plotted using the
Kaplan–Meier method, and statistical differences were
Table 2 Correlation of NDRG2 expression with clinical
histopathological characteristics in 143 ESCC specimens
Variable NDRG2 expression p
Negative (%) Positive (%)
Gender
Male 57 (60.0) 38 (40.0) 0.154a
Female 26 (54.2) 22 (45.8)
Age(years)
≤60 50 (64.1) 28 (35.9) 0.127 a
>60 33 (50.8) 32 (49.2)
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were considered statistically significant.
Results
Association between decreased expression of NDRG2 and
progression of ESCC
To further examine whether expression of the NDRG2
protein is linked to the clinical progression of ESCC, the
following samples were subjected to IHC staining with
a human NDRG2 antibody: 143 paraffin-embedded,
archived ESCC tissue samples, including 5 cases of stage I,
64 cases of stage IIA, 23 cases of stage IIB, 38 cases of
stage III and 13 cases of stage IV tumors. The mean age of
the 143 ESCC patients was 62 years (range 38 to 86 years),
and follow-up data were available for all patients.
The results of IHC staining are summarised in Table 1.
The NDRG2 protein was highly expressed in 60 of 143
(42.0%) human ESCC samples. Statistical analyses showed
no relationship between patient gender or age and NDRG2Table 1 Clinicopathological characteristics of patient






Male 95 (66.4) No 51 (35.7)
Female 48 (33.6) Yes 92 (64.3)
Age(years) Alcohol drinking
≤60 78 (54.5) No 37 (25.9)
>60 65 (45.5) Yes 106 (74.1)
Clinical stage T classification
I 5 (3.5) T1 9 (6.3)
IIA 64 (44.8) T2 52 (36.4)
IIB 23 (16.1) T3 63 (44.1)
III 38 (26.6) T4 19 (13.2)
IV 13 (9.0) Histological differentiation
N classification Well 45 (31.4)
N0 61 (42.7) Moderate 50 (35.0)
N1 69 (48.3) Poor 48 (33.6)
N2 13 (9.0) Expression of NDRG2
M classification Negative 83 (58.0)
M0 130 (90.9) Positive 60 (42.0)
M1 13 (9.1) Location
Therapy Upper 17 (11.9)
Surgery only 80 (55.9) Middle 80 (55.9)
Surge + CT/
RT/CRT
63 (44.1) Lower 46 (32.2)
Complication
Yes 35 (24.5)
No 108 (75.5)expression (Table 2). However, NDRG2 expression de-
creased progressively through tumor stages I to IV. More-
over, NDRG2 expression in ESCC tissues with poor
differentiation was statistically significantly lower than that
in well or moderately differentiated ESCC tissues. The data
revealed that NDRG2 expression was strongly associated
with clinical stage (P = 0.009), T classification (P < 0.0001),Cigarette smoking
No 33 (64.7) 18 (35.3) 0.289 a
Yes 50 (54.3) 42 (45.7)
Alcohol drinking
No 17 (45.9) 20 (54.1) 0.121 a
Yes 66 (62.3) 40 (37.7)
Clinical stage
I 1 (20.0) 4 (80.0) 0.009b
IIA 29 (45.3) 35 (54.7)
IIB 15 (65.2) 8 (34.8)
III 28 (73.7) 10 (26.3)
IV 10 (76.9) 3 (23.1)
T classification
T1 1 (11.1) 8 (88.9) <0.0001b
T2 23 (44.2) 29 (55.8)
T3 43 (68.3) 20 (31.7)
T4 16 (84.2) 3 (15.8)
N classification
N0 22 (36.1) 39 (63.9) <0.0001b
N1 50 (72.5) 19 (27.5)
N2 11 (84.6) 2 (15.4)
M classification
M0 72 (55.4) 58 (44.6) 0.036a
M1 11 (84.6) 2 (15.4)
Histological differentiation
Well 18 (40.0) 27 (60.0) 0.005b
Moderate 30 (60.0) 20 (40.0)
Poor 35 (72.9) 13 (27.1)
a Statistical analyses were done by the Fisher’s exact test.
b Statistical analyses were done by the Pearson’s chi square test.
A P value of < 0.05 was considered significant.
Figure 1 Correlation of the overall survival rate of ESCC
patients with NDRG2 expression pattern. Curves were estimated
using the Kaplan-Meier method (P < 0.0001). Continuous line
represents NDRG2 positive group; dotted line represents NDRG2
negative group.
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and histological differentiation (P = 0.005) (Table 2). Spear-
man analysis also revealed a correlation between NDRG2
expression and the clinical stage (r =−0.299, P < 0.0001),
T classification (r =−0.347, P < 0.0001), N classification
(r = −0.387, P < 0.0001), M classification (r = −0.170, P =
0.042) and histological differentiation (r = −0.268, P =
0.001) (Table 3). Taken together, these observations sup-
port the hypothesis that the progression of ESCC is asso-
ciated with decreased NDRG2 expression.
Association between expression of NDRG2 and overall
survival of ESCC patients
A log-rank test and Kaplan-Meier analysis were used to
calculate the effect of NDRG2 on survival. The log-rank
test showed that NDRG2 protein expression was strongly
related to patients’ survival time (P < 0.0001; Figure 1).
More specifically, the median survival time of patients
with high NDRG2 protein expression levels was 39
months, whereas the median survival time of those with
low NDRG2 levels was only 19 months. The cumulative
5-year survival rate was 36.1% in the high NDRG2 expres-
sion group, whereas in the low NDRG2 expression group,
the survival rate was only 6.7%.
Up-regulation of NDRG2 expression by Ad-NDRG2 in
Eca-109 cells
To examine NDRG2 expression in ESCC cell lines, we
detected NDRG2 protein expression in the normal hu-
man oesophageal epithelial cell line HEEC and five
ESCC cell lines (EC8712, KYSE30, Eca-109, KYSE70 and
KYSE150) by western blot. The results showed that the
expression of NDRG2 was the highest in the HEEC cell
line, followed by the EC8712, KYSE70 and KYSE150 cell
lines, and it was the lowest in the Eca-109 and KYSE30
cell lines (Figure 2A). To further determine the role of
NDRG2, we chose to use Eca-109 (low endogenousTable 3 Spearman correlation analysis between NDRG2
expression and clinical pathologic factors




Cigarette smoking .101 .232
Alcohol drinking -.145 .084
Clinical stage -.299 .0001
T classification -.347 .0001
N classification -.387 .0001
M classification -.170 .042
Histological differentiation -.268 .001
a The Spearman correlation test was used for statistical analyses. P values
< 0.05 were considered statistically significant.NDRG2 levels) as our experimental model in the follow-
ing studies. An adenovirus-NDRG2 construct was
designed to increase the expression levels of NDRG2.
Moreover, it was shown that subcellular localisation of
NDRG2 was observed in the cytoplasm of Eca-109 cells
(Figure 2B). The infection efficiency of Ad-NDRG2 in
Eca-109 cells was also examined (Figure 2C). Next, west-
ern blot was used to evaluate NDRG2 protein expression
up-regulation. Compared to the Ad-LacZ group (the
negative control), the expression of NDRG2 was success-
fully increased in Eca-109 cells after infection with
Ad-NDRG2 (Figure 2D).
Inhibitive effects of up-regulating NDRG2 on the growth
of Eca-109 cells
To investigate the inhibition of Eca-109 cell growth by
up-regulating NDRG2, MTT, colony formation and
DNA replication activity assays were examined. First, an
MTT assay was designed with an MOI gradient (1, 10,
and 100) and infection time gradient (day 1, day 2, and
day 3). We infected cells with Ad-NDRG2 or Ad-LacZ
at an MOI of 1, 10, and 100; after 48 h treatment, the
proliferation of the Ad-LacZ group was not significantly
different compared to the control. On the contrary, the
inhibition ratio of the Ad-NDRG2 group was augmented
by increasing the Ad-NDRG2 concentration (Figure 3A).
There was also a clear time dependence of Ad-NDRG2
efficacy, with only moderate inhibition of proliferation at
24 h and maximal inhibition achieved at 48 h. Extending
the incubation period to 72 h showed no further in-
crease in the inhibitory efficacy (Figure 3B). Next, we
assayed the contribution of Ad-NDRG2 in Eca-109 cell
colony formation. The different groups were incubated
for 2 weeks and counted. As shown in Figure 3C and
3D, compared with the control, the colony formation
Figure 2 Up-regulation of NDRG2 expression by Ad-NDRG2 in Eca-109 cells. A. HEEC cells (a normal human oesophageal epithelial cell line)
and five ESCC cell lines (EC8712, KYSE30, Eca-109, KYSE70 and KYSE150) were collected for protein extraction and analysed for NDRG2 expression
using western blot. B. Subcellular localisation of NDRG2 in Eca-109 cells. Eca-109 cells were fixed and incubated with a primary anti-NDRG2
monoclonal antibody and a CY3 secondary antibody. Red fluorescence (NDRG2) was observed in the cytomembrane and cytoplasm of Eca-109
cells. Blue fluorescence indicates DAPI nuclear staining. C. Immunofluorescence showed the efficiency of Ad-NDRG2 infection (red). D. Western
blot analysis of NDRG2 in Eca-109 cells infected with Ad-NDRG2. Equal amounts of protein (80 μg/lane) were subjected to western blot analysis
as described in the Methods.
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to only 33.6%. In contrast, there was no obvious differ-
ence in the colony formation ratio between the control
and Ad-LacZ groups. Last, the cell DNA replication ac-
tivity was examined using BrdU, a synthetic thymidine
analogue that binds to replicating DNA. We performed
a BrdU assay and found that, after 3 h incubation with
BrdU, the cells in the DNA replication phase presented
a red colour. As shown in Figure 3E and 3F, compared
to the control, the red cell ratio of Ad-NDRG2-treated
cells was just 28.6%. There was no obvious difference in
the DNA replication activity between the control and
Ad-LacZ groups. These data revealed that NDRG2
overexpression could inhibit the growth of Eca-109 cells.
Suppression of tumor growth in a nude mouse model by
intratumoural Ad-NDRG2 injection
To investigate the effects of Ad-NDRG2 on tumor growth
in vivo, we injected 1 × 109 PFU Ad-NDRG2, Ad-LacZ, or
PBS every 3 days into pre-established human Eca-109
ESCC tumours (approximately 200 mm3) grown in nude
mice. As shown in Figure 4A and B, the Ad-NDRG2
group achieved a sustained and significant arrest of
tumour growth (66.7% decrease in mean tumour volume
on day 24 compared with the control group), whereas the
growth of tumours injected with Ad-LacZ was notsignificantly inhibited (3.8% decrease compared with the
control group). We sacrificed the mice 24 days after begin-
ning intratumoural injections and removed the tumours
for the protein expression analysis (Figure 4C). Immu
nolabelling with cyclinD1 and Ki67 were examined in tu-
mours excised from the mice. Moreover, the cyclinD1 and
Ki67 expression levels in the Ad-NDRG2 group were de-
creased dramatically compared with the control group.
There was no significant difference between the control
and Ad-LacZ groups.
Discussion
Although surgical resection and adjuvant therapy are
commonly used in oesophageal carcinoma patients, the
overall survival rate of oesophageal cancer remains very
low. The development of biological therapies for oe-
sophageal carcinoma is therefore urgently required. Earlier
studies have shown that NDRG2, a new tumour suppres-
sor gene, is lowly expressed and correlates with the pro-
gression of breast cancer [17]. However, the correlation of
NDRG2 with ESCC and the effect of NDRG2 on ESCC
cell growth are currently unclear. In this study, we
analysed the correlation of NDRG2 expression with
clinical stage, TNM clinical classification, histological dif-
ferentiation and survival time in the ESCC patients. More-
over, we used an adenovirus-mediated gene expression
Figure 3 Up-regulating NDRG2 inhibits Eca-109 cell growth. A. Dose-dependent suppression of Eca-109 cell proliferation by Ad-NDRG2.
Eca-109 cells were infected with various amounts of Ad-NDRG2 or Ad-LacZ (at MOI of 1, 10, and 100) and incubated for 48 h. Cell proliferation
was detected by MTT assay. B. Time-dependent suppression of Eca-109 cell proliferation by Ad-NDRG2. After Ad-NDRG2 or Ad-LacZ infection at
an MOI of 100, the cells were incubated for different time periods (24, 48 and 72 h). Cell proliferation was detected by MTT assay. C and D. The
effect of Ad-NDRG2 on Eca-109 cell colony formation was examined. After Ad-NDRG2 or Ad-LacZ infection, the cells were incubated for
approximately 10 days until visible cell colony formation. Only the clearly visible colonies (diameter > 50 μm) were counted. E and F. The effect of
Ad-NDRG2 on Eca-109 cell DNA replication activity was examined. After Ad-NDRG2 or Ad-LacZ infection, the cells were incubated for 2 days and
cultured with BrdU for 1 h and DAPI for nuclear counterstaining. The results were analysed using a fluorescence microscope; BrdU positive (red)
cells were counted. Data are mean ± SD from three independent experiments. Statistical significance was assessed using a one-way ANOVA and
Student’s t-test. * or ** indicates P < 0.05 or P < 0.01, respectively, compared to the control.
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Eca-109, to directly investigate the effect of NDRG2 on
cell growth in vitro and in vivo.
Members of the human NDRG family, comprising
NDRG1, NDRG2, NDRG3 and NDRG4, share 57%-65%
amino acid identity [18]. Although we do not yet fully
understand the roles of the NDRG family members, it is
possible that these proteins have a crucial function in
tumour progression and differentiation. Previous studies
have shown that NDRG2 was highly expressed in adult
brain and skeletal muscle and almost undetectable in
some human cancer lines [19-21], suggesting that it may
play important functions in different tissues. It was
reported that the expression level of NDRG2 mRNA was
very high in brain, salivary gland, skeletal muscle and
mammary gland; low in bone marrow, testis, peripheralblood and placenta; and not detectable in leukocytes,
colon and some tumour cell lines [22-24]. Recent reports
have shown that NDRG2 was differentially expressed in
tumour and normal tissues, and NDRG2 expression was
consistently down-regulated in grade Ш meningioma at
both the transcriptional and translational levels [25]. Fur-
ther studies have found that NDRG2 inhibits the prolifera-
tion, adhesion and invasion of breast cancer cells [26,27].
In addition, a previous study reported that NDRG2 could
inhibit the metastatic potential of breast cancer cells, spe-
cifically via the suppression of CD24 or MMP-9 expres-
sion. Tumour angiogenesis in breast cancer was inhibited
by overexpression of NDRG2 up-regulating the expression
of p53 and VHL and down-regulating the expression of
VEGF and HIF-1α [28]. NDRG2 could suppress cell prolif-
eration possibly through the following mechanisms: first,
Figure 4 Effects of intratumoural Ad-NDRG2 injections on the growth of Eca-109 cells xenografted into mice. Eca-109 cells (5 × 106) were
injected into the upper hind limb of athymic nude mice and allowed to grow until the tumour volume reached 200 mm3. Mice then received
intratumoural Ad-NDRG2 or Ad-LacZ injections (at 50 MOI) or PBS (20 μl as control) every 3 days. A. Tumour growth curve. The tumour growth
was assessed every 3 days until Day 24 of treatment by measuring two perpendicular diameters and calculating the volume in mm3. Statistical
analysis was performed on Day 24 values only, using a one-way ANOVA and Student’s t-test. ** indicates P < 0.01 as compared to the control.
B. Representative photographs of xenografted tumours are shown. C. Intratumoural the protein expression was assessed by cyclinD1-immunolabeling
(400 × magnification) or Ki67-immunolabeling (400 × magnification) on paraffin-embedded Eca-109 cell tumour sections. Representative images are
shown. Statistical analysis was carried out using a one-way ANOVA. The results are shown as the mean ± SD of three different fields per mouse from a
total of six mice. **P < 0.01.
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β-catenin activity, both of which are critical signaling
pathways in cell growth [29,30]; second, NDRG2 could
suppress nuclear factor kappa B (NF-kB) activity, sugges
ting a possible mechanism for NDRG2 to participate in
carcinogenesis and progression of human malignancy
[31,32]; third, silencing NDRG2 attenuates p53-mediated
apoptosis, and p53 could increase NDRG2 expression to
promote tumor cell apoptosis, suggesting that NDRG2
also suppresses tumor cell proliferation through the p53-
mediated apoptosis signaling pathway [12].
The expression and effects of NDRG2 in ESCC are
unclear. In this paper, our data suggest that in ESCC tis-
sues, NDRG2 expression decreased progressively through
tumour stages I to IV, and NDRG2 expression in the well-
differentiated ESCC tissues was significantly high. The
data revealed that NDRG2 expression was strongly associ-
ated with the TNM clinical stage. Importantly, an overall
survival analysis revealed that positive NDRG2 expression
was correlated with longer survival time in ESCC patients.
Lastly, in vitro and in vivo NDRG2 up-regulation could
inhibit Eca-109 cell proliferation, decrease the cloneformation number and the DNA replication activity of
Eca-109 cells. Moreover, in a nude mouse model of ESCC,
Ad-NDRG2 treatment achieved a sustained and significant
arrest of tumour growth, and expression of cyclinD1 and
Ki67 was lower in tumours excised from mice in the Ad-
NDRG2 group.Conclusion
In summary, our results provide evidence that NDRG2
contributes to the growth of ESCC. NDRG2 expression cor-
relates with ESCC TNM stage, tumour differentiation and
overall survival of ESCC patients, and up-regulating
NDRG2 expression by adenovirus could inhibit the growth
of ESCC cells in vitro and in vivo. Thus, our study provides
evidence that NDRG2 may play an important role in the
development, differentiation, and carcinogenesis of ESCC
and could therefore be utilised in diagnosis and as a prog-
nosis indicator in ESCC patients.Competing interests
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